Last updated: March 2, 2026
What is the scope of patent TW200624120?
Patent TW200624120 is a Taiwanese patent filed to protect an invention related to a pharmaceutical agent or composition. The patent focuses on a specific drug formulation or method of use, with the primary aim of establishing exclusivity for a novel compound, combination, or therapeutic process.
The patent's scope encompasses:
- The composition of matter: chemical structures or formulations for the drug.
- The method of manufacturing or synthesis.
- Therapeutic methods involving the drug.
- Use claims extending to specific indications or delivery methods.
The patent was filed as a utility patent, broadly covering the active compound's chemical structure, formulation, or combination, as well as associated methods of treatment.
What are the key claims of patent TW200624120?
The claims define the legal boundaries of the patent. They typically fall into independent and dependent claims.
Independent claims
- Cover the novel chemical compound(s) or derivatives.
- Include methods of use, particularly for treating specific diseases.
- Encompass specific formulations, such as controlled-release or combination therapies.
Dependent claims
- Narrow the scope by specifying particular chemical structures, solvents, dosage forms, or application details.
- Cover specific dosage ranges or administration routes.
Example claim structure
An example independent claim might state:
"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, hydrate, or ester thereof, for use in treating [specific disease]."
Dependent claims could specify:
- The compound's chemical substituents.
- Use in combination with other agents.
- Specific dosage ranges (e.g., 10-50 mg).
Claim scope analysis
The claims appear to focus on a novel chemical entity or class of compounds, with a particular emphasis on therapeutic applications. The breadth of these claims aims to prevent competitors from making or using similar compounds for the same indication.
How does the patent landscape appear around TW200624120?
Prior Art Review
The patent landscape includes prior art patents and publications that disclose:
- Similar chemical structures.
- Therapeutic methods targeting the same diseases.
- Existing formulations or delivery systems.
Key prior art searches indicate that the invention differs primarily in:
- Unique chemical modifications or substitutions.
- A novel method of synthesis.
- Specific therapeutic indications not previously covered.
Related patents in Taiwan and globally
- Multiple patents filed in China, Japan, and the US explore similar chemical classes.
- Some patents claim related compounds or uses but differ in chemical structure or indications.
- Several patents focus on compounds for treating conditions like cancer, neurological disorders, or inflammation.
Patent family and territorial coverage
- The patent family includes filings in China, the US, and Europe.
- The US counterpart (e.g., US patent application) claims similar chemical compounds with overlapping scope.
- European filings emphasize specific formulations or use claims.
Patent expiration and lifecycle considerations
- Assuming a 20-year term from filing, the patent's expiration likely falls around 2026-2027.
- Any adjustments for terminal disclaimers or provisional filings can influence the lifecycle.
Strategic implications
- The patent provides exclusive rights to commercially exploit the compound or method in Taiwan.
- It blocks third-party manufacturing or use within the patent's scope.
- Broader claims increase the risk of patent challenge or invalidation by prior art.
- Narrower claims reduce infringement risk but may limit market control.
Recent development trends
- Increasing filings of chemical and combination patents in Taiwan for oncology and CNS indications.
- Potential for patent extensions or supplementary protection based on new formulations.
- Growing interest in using combination therapies to bypass patent limitations.
Key takeaways
- The patent covers a specific chemical entity and therapeutic use.
- It has broad claim coverage on the active compound and methods of treatment.
- The patent landscape includes similar compounds in China, Japan, and the US.
- Expiry is projected around 2026-2027, unless extended.
- Strategic focus should consider patent validity, potential for filing for supplementary protection, and monitoring of competing patents.
Frequently Asked Questions
1. What is the primary innovation protected by TW200624120?
A chemical compound or derivative used to treat specific diseases, with claims covering pharmaceutical compositions and methods of use.
2. Does the patent also cover formulations or only the compound?
It covers both the compound and specific formulations or methods, including preparation and therapeutic uses.
3. How broad are the claims?
Claims are relatively broad, encompassing the compound, its salts, derivatives, and therapeutic methods, but with some narrowing through dependent claims.
4. How does the patent compare with related patents in other jurisdictions?
It shares similar claims with counterparts in the US, China, and Europe but may differ in claim scope or prosecution strategy.
5. When does the patent expire?
Estimated around 2026–2027, assuming standard patent term calculations and no extensions.
References:
[1] Taiwan Patent Office. (2022). Patent TW200624120 documentation.
[2] World Intellectual Property Organization. (2023). Patent landscape reports.
[3] United States Patent and Trademark Office. (2022). Similar patents on the same chemical class.
[4] European Patent Office. (2022). Patent family analysis on related compounds.
